Asheville – Health treatment is evolving and the partnership between Living Medicine Institute (LMI) and Blossom is a significant step forward. This collaboration aims to enhance the understanding and application of psychedelic-assisted psychotherapy, a field that has garnered increasing attention for its potential to treat various mental health disorders.
A New Era of Collaboration
Living Medicine Institute, based in Asheville, N.C., has established itself as a leading training center for clinicians interested in psychedelic-assisted psychotherapy. The recent partnership with Blossom, a prominent research hub focused on psychedelic therapy, will provide LMI’s Psychedelic Provider Network (PPN) with monthly updates on the latest scientific findings. This initiative is designed to keep practitioners informed about advancements in the field, ensuring they have access to the most accurate and relevant information.

Dr. Sandy Newes, co-founder of LMI, expressed enthusiasm about the collaboration. “We look forward to the collaboration with Floris Wolswijk, the founder of Blossom,” said Newes, PhD. “As one of the world’s leading sources of information on psychedelic research, Blossom will help us share about the research quickly and easily within our member-based community.”
Enhancing Resources for Practitioners
The Psychedelic Provider Network serves as an online resource for practitioners eager to learn more about psychedelic medicine, including ketamine therapy. The updates from Blossom will significantly enrich the resources available to PPN members. Dr. Signi Goldman, MD, also a co-founder of LMI, highlighted the importance of comprehensive research access. “Blossom is really devoted to combing the literature, making sure that he’s being comprehensive,” she said. “This partnership allows us to cross-reference what we already had and build in what he has to ensure our database is really comprehensive.”
With more than 2,100 research papers and results from more than 900 clinical trials in its database, Blossom offers a wealth of information on various drug compounds and their efficacy in treating conditions like depression and PTSD. The collaboration will focus on sharing research specifically relevant to psychedelic-assisted psychotherapy, providing practitioners with expertly vetted content.
The Significance of Research in Psychedelic Therapy
The landscape of psychedelic medicine is rapidly changing, and staying informed is crucial for clinicians. The partnership between LMI and Blossom aims to address this need by providing a reliable source of information. “Through our database and in collaborating with Blossom, we’re really able to make sure that not only is it comprehensive, but it’s actually quality research that’s expertly vetted,” Dr. Goldman explained.
As the field continues to grow, understanding the nuances of psychedelic therapy becomes increasingly important. The updates from Blossom will help practitioners navigate this complex landscape, ensuring they are equipped with the latest findings and methodologies.
Key Areas of Focus for Future Research
Looking ahead, both Goldman and Newes anticipate that certain topics will be particularly valuable to their community. “Tracking the research right now is maybe even more important than ever,” Newes noted. Recent developments, such as the FDA’s decision regarding MDMA approval, underscore the need for ongoing research and understanding of therapeutic methodologies.
The partnership will emphasize not just the medicines themselves but also the therapeutic processes that accompany them. “Let’s look at psilocybin plus psychotherapy, and then let’s look at the different types of intervention models that people are doing,” Goldman suggested. This holistic approach aims to enhance patient outcomes by integrating psychotherapy with psychedelic treatments.
A Commitment to Responsible Practice
Both LMI and Blossom share a commitment to responsibly implementing psychedelic-assisted psychotherapy in mental health treatment. Their collaboration is rooted in a shared goal: to use research to inform practices that prioritize safety and efficacy.
As Goldman stated, “People are screaming out for a change in mental health, and this has the potential to be it.” The partnership between Living Medicine Institute and Blossom represents a proactive step toward achieving that change through informed practice and ongoing research.
In conclusion, this collaboration not only enhances the resources available to practitioners but also reinforces the importance of scientific inquiry in the evolving field of psychedelic therapy. As LMI continues to lead in training and resources for clinicians, the partnership with Blossom promises to keep its community at the forefront of this transformative approach to mental health treatment.